The bulge sign - a simple physical examination for identifying progressive knee osteoarthritis: data from the Osteoarthritis Initiative.
Yuanyuan Wang, Johanne Martel-Pelletier, Andrew J Teichtahl, Anita E Wluka, Sultana Monira Hussain, Jean-Pierre Pelletier, Flavia M Cicuttini
Rheumatology | British Society for Rheumatology | Published : 2020
OBJECTIVE: To examine whether the presence of bulge sign or patellar tap was associated with frequent knee pain, progression of radiographic OA (ROA) and total knee replacement (TKR). METHODS: This study included 4344 Osteoarthritis Initiative participants examined at baseline for bulge sign and/or patellar tap. The clinical signs were categorized as no (none at baseline and 2 years), resolved (present at baseline only), developed (present at 2 years only) and persistent (present at both time points). Frequent knee pain and progression of ROA over 4 years and TKR over 6 years were assessed. Binary logistic regression was used to examine the associations. RESULTS: A total of 12.7% of particip..View full abstract
Awarded by National Institutes of Health, a branch of the Department of Health and Human Services
The OAI is a public-private partnership comprised of five contracts (NO1-AR-2-2258, NO1-AR-2-2259, NO1-AR-2-2260, NO1-AR-2-2261, NO1-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, in four clinical sites (University of Maryland School of Medicine and Johns Hopkins University, Baltimore, MD; Ohio State University, Columbus, OH; University of Pittsburgh, Pittsburgh, PA; Memorial Hospital of Rhode Island, Pawtucket, RI) and conducted by the OAI study investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals, GlaxoSmithKline and Pfizer. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health.